STUDIES OF NEW SYMPATHOMIMETIC BETA-RECEPTOR STIMULATING DRUGS IN ASTHMATIC PATIENTS: III. A COMPARATIVE TRIAL OF SUBCUTANEOUS TERBUTALINE AND TRIMETOQUINOL

By J. L. Da Costa, B. K. Goh, H. Y. Lee and P. C. Teoh

SYNOPSIS

A comparative study of the effect of subcutaneous terbutaline (0.5 mg.) and trimetoquinol (0.1 mg.) on the relief of airway obstruction and the heart rate was carried out in 14 asthmatic patients. Terbutaline produced significantly greater increases (p < 0.001) in PEFR than trimetoquinol up to three hours after parenteral drug administration. Both drugs produced significant increases in heart rate up to thirty minutes after drug administration but there were no differences between the two drugs in this respect and side effects were negligible. It was concluded that in the dosages used terbutaline produced a superior bronchodilator effect with a greater peak level and a longer duration of action than trimetoquinol.

Lands et al (1967) established that sympthomimetic amines stimulated the heart and produced bronchodilatation through activation of the beta₁ and beta₂ adrenoreceptors. This prompted the development of more selective bronchodilator (beta₂ adrenoreceptor stimulators) agents with little cardiovascular effects. Salbutamol (Hartley et al, 1968) has been shown to be a selective beta₂ adrenoreceptor stimulator and is now widely used in asthmatic patients. Recently, two other drugs terbutaline (Formgren, 1970; Arner et al, 1970; Da Costa and Goh, 1973) and trimetoquinol (Iwasawa and Kiyomoto, 1967; Yamamura and Kishimoto, 1968) have been shown to have powerful selective bronchodilator activity. This paper reports the effect of subcutaneous terbutaline and of trimetoquinol on the relief of airway obstruction and the heart rate.

MATERIALS AND METHODS

Fourteen patients (10 males and 4 females) with bronchial asthma were investigated. Their mean age was 32 years (range 18-58 years).

Department of Medicine, University of Singapore. Medical Unit I, The General Hospital, Singapore.
J. L. DA COSTA, A.M., M.D. (S'pore), M.R.C.P. (Glasg), F.R.C.P. (Ed), F.C.C.P. (USA), Associate Professor.
B. K. GOH, Senior Laboratory Technician.
H. Y. LEE, A.M., M.R.C.P. (UK), Lecturer. P. C. TEOH, A.M., M.Med. (S'pore), M.R.C.P. (UK), Senior Lecturer.

The reversibility of their airways obstruction was tested the day before the start of the trial. After two inhalations of orciprenaline aerosol (1.5 mg. orciprenaline) they had to show an increase in peak expiratory flow rate (PEFR) of at least 15 per cent. No other bronchodilator drugs were given later than 10 hours before the start of the trial. Six patients who were on oral steroid therapy continued to receive the same dose during the trial.


The trial was performed as a cross-over study, the tests being performed between 9 a.m. and 3 p.m. on two consecutive days as far as possible. A subcutaneous dose of 0.1 mg. trimetoquinol or 0.5 mg. terbutaline was given on different days, consecutively. The drugs were injected slowly over 3 minutes. PEFR was recorded using a Wright's peak flow meter (Wright et al, 1959) before, and at 15 and 30 minutes and 1, 2, 3, 4, 5 and 6 hours after the injection. All measurements were made with the same apparatus while the subjects were seated. The best value of five measurements at each time period was used for the calculations. The heart rate was also measured at the same periods before and after each injection and any side effects experienced by the patients were also recorded.

RESULTS

(a) **PEFR**

Mean values of the PEFR in the 14 asthmatic patients studied before and after parenteral ad-

ministration of terbutaline and trimetoquinol, respectively, are given in Table I. It was not possible to make a statistical evaluation beyond 3 hours as in some patients the test was dis-



continued after this period because the PEFR had fallen below the baseline.

Both drugs had a rapid onset of action reaching a peak within $\frac{1}{2}$ hour (Fig. 1). The PEFR after terbutaline remained at this peak level for 2 hours and then fell slightly and at 3 hours it was still significantly raised (p<0.001). After trimetoquinol however there was a rapid fall of the PEFR from the peak level at 15 minutes and it reached the basal level by 2 hours. Comparison of the differences between the changes produced by both drugs showed that terbutaline produced significantly greater (p<0.001) increases in PEFR at all specified time intervals (Table I).

(b) Heart Rate (Table II and Fig. 2)

After administration of both drugs maximal increase in heart rate occurred within 30 minutes




Fig. 1. Peak Expiratory Flow Rate (PEFR) (L/min): Mean values in 14 asthmatic patients before and at specified intervals after subcutaneous injection of terbutaline and trimetoquinol.

Fig. 2. Heart Rate (beats/min): Mean values of the heart rate in 14 asthmatic patients before and at specified intervals after subcutaneous injection of terbutaline and trimetoquinol.

TABLE I

PEAK EXPIRATORY FLOW RATE (PEFR): MEAN VALUES IN 14 ASTHMATIC PATIENTS BEFORE AND MEAN VALUES OF INDIVIDUAL CHANGES AT SPECIFIED INTERVALS AFTER SUBCUTANEOUS INJECTION OF TERBUTALINE AND TRIMETOQUINOL

Drug	Dose (mg.)	Initial Value M SEM	PEFR (L/min) CHANGES AFTER SPECIFIED INTERVALS							
									15 mins M SEM	30 mins M SEM
			Terbutaline	0.5 .	233 25·7	+101‡ 8·4	+117‡ 9·9	+116‡ 10·9		
			Trimetoquinol	0.1	252 26·2	+61‡ 8·7	+48‡ 7·9	+25* 11·2	+3 8·1	-10 8·0
Difference be- tween changes			4.77‡	6.32‡	5.97‡	 8·96‡	6 ·2 3‡			

* Almost significant (p<0.05)

† Significant (p < 0.01)

‡ Highly significant (p<0.001)

M = mean

SEM = standard error of mean.

TABLE II

HEART RATE: MEAN VALUES IN 14 ASTHMATIC PATIENTS BEFORE AND MEAN VALUES OF INDIVIDUAL CHANGES AT SPECIFIED INTERVALS AFTER SUBCUTANEOUS INJECTION OF TERBUTALINE AND TRIMETOQUINOL

Drug	Dose (mg.)	Initial Value	HEART RATE BEATS/MIN					
			CHANGES AFTER SPECIFIED INTERVALS					
			15 mins M SEM	30 mins M SEM	1 hour M SEM	2 hours M SEM	3 hours M SEM	
								Terbutaline
Trimetoquinol	0.1	85·1 3·9	$+11\cdot1\ddagger \\ 2\cdot3$	+8·4‡ 1·9	+ 3·3 1·9	+1·7 2·0	+3·9* 1·5	
Difference be- tween changes			1.1	0.3	2.1	1•36	0.5	

Almost significant (p<0.05)
 Significant (p<0.01)

thighly significant (p<0.001)</pre>

and thereafter showed no significant increase over the basal level. There was no significant difference between the changes produced by each drug.

(c) Side effects

Two patients complained of palpitations after terbutaline within 15 minutes of drug administration while 1 had palpitations after trimetoquinol at 5 minutes.

DISCUSSION

Trimetoquinol a recently synthesized bronchodilator has been shown in recommended doses to have more selective bronchodilator activity with a negligible affect on the cardiovascular system (Kiyomoto et al, 1969). When inhaled as an aerosol it has been shown to have similar bronchodilator activity and effect on the pulse rate as salbutamol (Scherrer and Bachofer, 1972). Terbutaline (0.5 mg.) when used subcutaneously has been shown to be a powerful bronchodilator with a significantly longer duration of action than adrenaline (Da Costa and Goh, 1972) and little cardiovascular side effects (Da Costa and Goh, 1973). When compared with salbutamol, inhaled as an aerosol, it has been shown to be an equally effective bronchodilator agent (Choo-Kang et al, 1973). It was thus of interest to compare the effects of trimeM = mean

toquinol and terbutaline given subcutaneously as this has not been done before.

In the recommended therapeutic dosages used, terbutaline (0.5 mg.) demonstrated a superior bronchodilator effect to trimetoquinol (0.1 mg.) with a greater peak effect and a significantly longer duration of action. There was no significant difference in the effects on the cardiovascular system. 0.1 mg. trimetoquinol did not produce as great a peak effect as 0.5 mg. terbutaline in this study showing that they were not equipotential dosages. It would thus be of interest to study the effect of a higher or equipotential dosage of trimetoquinol. Preliminary studies, however, have demonstrated a greater incidence of cardiovascular side effects with a dosage of 0.2 mg. trimetoquinol and patient tolerance has been poor (Da Costa and Goh, unpublished observations).

ACKNOWLEDGEMENT

We would like to thank AB Astra, Sweden and Tanabe Seiyaku Co., Ltd, Japan for providing supplies of terbutaline (Bricanyl) and trimetoquinol (Inolin), respectively and also Dr. E. Pihlsgård for the statistical analyses.

REFERENCES

1. Arner, B.: "A comparative clinical trial of different subcutaneous doses of terbutaline and orciprenaline in bronchial asthma". Acta Med. Scand. Suppl., 512, 45, 1970.

- Choo-Kang, Y.F.J., MacDonald, H.L., Horne, N.W.: "Comparison of sabutamol and terbutaline aerosols in bronchial asthma". Practitioner, 211, 801, 1973.
- 3. Da Costa, J.L. and Goh, B.K.: "A comparative trial of subcutaneous Terbutaline, Th 1165a and Adrenaline in Bronchial Asthma". Med. J. Aust., 2, 588, 1973.
- Da Costa, J.L. and Goh, B.K.: "Studies of new sympathomimetic beta-receptor stimulating drugs in asthmatic patients I: The bronchodilator and circulatory effects of subcutaneous terbutaline". Sing. Med. J., 14, 120, 1973.
- Formgren, H.: "A clinical comparison of the effect of oral terbutaline and orciprenaline". Scand. J. Resp. Dis., 5, 195, 1970.
- Hartley, D., Jack, D, Lunts, L.H.C. and Ritchie, A.C.: "A new class of selective stimulants of betaadrenergic receptors". Nature (Lond), 219, 861, 1968.
- Iwasawa, Y. and Kiyomoto, A.: "Studies on tetrahydroisoquinoline (THI) (I): Bronchodilator activity and structure-activity relationship". Jap. J. Pharmacol., 17, 143, 1967.

- Kiyomoto, A., Sato, M., Nagao, T. and Nakajima, H.: "Studies on Tetrahydroisoquinolines (THI) (VII): Effect of trimetoquinol on the cardiovascular system". Europ. J. Pharmacol., 5, 303, 1969.
- Lands, A.M., Arnold, A., McAuliff, J.P., Luduena, F.P. and Brown, T.G. Jr.: "Differentiation of receptor systems activated by sympathomimetic amines". Nature (Lond), 214, 597, 1967.
- Mattila, M.J. and Muittari, A.: "The effects of bronchodilator aerosols on the peak expiratory flow rate in asthmatic patients". Acta Med. Scand., 180, 421, 1966.
- 421, 1900.
 11. Scherrer, M. and Bachofen, H.: "Vergleich der wirkung einer 4½ Minuten daurnden Aerosolinhalation von Salbutamol und Trimetoquinol mit derjenigen einer 10—15 Minuten daurnden Tacholiquin-Oricprenaline Inhalation bei Bronchial asthma". Schweiz. Med. Wschr., 102, 909, 1972.
- Wright, B. and McKerrow, C.B.: "Maximum forced expiratory flow as a measure of ventilatory capacity". Brit. Med. J., 2, 1041, 1959.
- Yamamura, Y. and Kishimoto, S.: "Clinical effectiveness of a new bronchodilator, Inolin, on bronchial asthma". Ann. Allergy, 26, 504, 1968.